Epizyme Inc (EPZM) Stock
EPZM is no longer traded. Epizyme was delisted from the Nasdaq in August 2022.
Prices on this page are historical; the last trade was August 11, 2022 at $1.47.
Epizyme stock price history
EPZM final trading statistics
- Final close
- $1.47
- Final trading day
- Aug 11, 2022
- Market cap at delisting
- $247.50M
- Shares outstanding
- 168.36M
- Final 52-week range
- $0.41 – $5.80
- Avg. volume (final 3 mo.)
- 4,322,841
- All-time high (split-adj.)
- $43.60 · Jul 2013
- All-time low (split-adj.)
- $0.41 · Jun 2022
- Return since IPO
- -93.6%
- Beta
- -0.42
- Book value / share
- $0.85
- Price / book
- 1.73
Epizyme annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $37.43M | -$251.1M | -$2.45 |
| FY2020 | $15.76M | -$231.7M | -$2.29 |
| FY2019 | $23.80M | -$170.3M | -$1.91 |
| FY2018 | $21.70M | -$123.6M | -$1.74 |
| FY2017 | $10.00M | -$134.3M | -$2.19 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Epizyme Inc
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Epizyme stock FAQ
What happened to Epizyme stock?
Epizyme stock was delisted from the Nasdaq. Its final close was $1.47 on August 11, 2022.
Is EPZM stock still trading?
No. EPZM was delisted from the Nasdaq in August 2022 and no longer trades on a U.S. exchange.
What was the last price of EPZM stock?
EPZM closed at $1.47 on its final trading day, August 11, 2022, for a market value of about $247.50M.
What were Epizyme's revenue and earnings in its last full fiscal year?
Epizyme reported revenue of $37.43M and net income of -$251.1M in fiscal 2021, its last full year as a public company.
When did Epizyme go public?
Epizyme Inc stock began trading on May 31, 2013.